CY1113433T1 - Σταθερος υδριτης ενος ανταγωνιστη υποδοχεα μουσκαρινης - Google Patents
Σταθερος υδριτης ενος ανταγωνιστη υποδοχεα μουσκαρινηςInfo
- Publication number
- CY1113433T1 CY1113433T1 CY20121101165T CY121101165T CY1113433T1 CY 1113433 T1 CY1113433 T1 CY 1113433T1 CY 20121101165 T CY20121101165 T CY 20121101165T CY 121101165 T CY121101165 T CY 121101165T CY 1113433 T1 CY1113433 T1 CY 1113433T1
- Authority
- CY
- Cyprus
- Prior art keywords
- bladder
- disease
- treatment
- stable
- neurogenic
- Prior art date
Links
- 230000002860 competitive effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010056948 Automatic bladder Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010013554 Diverticulum Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 206010020853 Hypertonic bladder Diseases 0.000 abstract 1
- 206010027566 Micturition urgency Diseases 0.000 abstract 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 abstract 1
- 206010029279 Neurogenic bladder Diseases 0.000 abstract 1
- 208000004880 Polyuria Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 208000029162 bladder disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000028299 esophageal disease Diseases 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 201000003890 low compliance bladder Diseases 0.000 abstract 1
- 230000027939 micturition Effects 0.000 abstract 1
- 239000003149 muscarinic antagonist Substances 0.000 abstract 1
- 230000001272 neurogenic effect Effects 0.000 abstract 1
- 230000002040 relaxant effect Effects 0.000 abstract 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 230000001148 spastic effect Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 208000026533 urinary bladder disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Ένας σταθερός στερεός υδρίτης ενός ανταγωνιστή μουσκαρινικού υποδοχέα είναι ωφέλιμος στη θεραπεία ασθενειών όπως το σύνδρομο του ευερέθιστου εντέρου, η ασθένεια του εκκολπώματος, η ασθένεια του μεγαοισοφάγου, η χρόνια αποφρακτική ασθένεια των αεραγωγών, η υπερδραστήρια κύστη (με συμπτώματα την ακράτεια, την επιτακτική ανάγκη και τη συχνότητα), η ακράτεια ούρων, η νευρογενής επιτακτική ανάγκη ούρησης ή πολλακιουρία, η αγωγή της λειτουργικής διαταραχής της κύστης, η διαρροή της ουροδόχου κύστεως, η επίπονη ή δύσκολη ούρηση που οφείλεται σε νευρογενή κύστη, η σπαστική ή υπερτονική κύστη, το σύνδρομο δυσλειτουργικής κύστεως, οι γαστροεντερικές διαταραχές όπως η γαστροεντερική υπερ-δραστηριότητα, και η χαλαρωτική δράση στα λεία μυϊκά κύτταρα του εντέρου.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0207104.1A GB0207104D0 (en) | 2002-03-26 | 2002-03-26 | Stable hydrate of a muscarinic receptor antagonist |
| EP10177716A EP2336124B1 (en) | 2002-03-26 | 2003-03-17 | Stable hydrate of a muscarinic receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113433T1 true CY1113433T1 (el) | 2016-06-22 |
Family
ID=9933731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111100213T CY1111200T1 (el) | 2002-03-26 | 2011-02-22 | Διαλυτης τολουενιου της δαριφενακινης |
| CY20121101165T CY1113433T1 (el) | 2002-03-26 | 2012-11-29 | Σταθερος υδριτης ενος ανταγωνιστη υποδοχεα μουσκαρινης |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111100213T CY1111200T1 (el) | 2002-03-26 | 2011-02-22 | Διαλυτης τολουενιου της δαριφενακινης |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US6930188B2 (el) |
| EP (2) | EP1490357B1 (el) |
| JP (2) | JP2005524678A (el) |
| KR (4) | KR101212908B1 (el) |
| CN (1) | CN100345840C (el) |
| AR (1) | AR042608A1 (el) |
| AT (1) | ATE495169T1 (el) |
| AU (1) | AU2003209921A1 (el) |
| BR (2) | BRPI0308706B8 (el) |
| CA (1) | CA2480287C (el) |
| CY (2) | CY1111200T1 (el) |
| DE (1) | DE60335711D1 (el) |
| DK (2) | DK1490357T3 (el) |
| ES (2) | ES2394067T3 (el) |
| GB (1) | GB0207104D0 (el) |
| HK (2) | HK1080847A1 (el) |
| PA (1) | PA8569701A1 (el) |
| PT (2) | PT1490357E (el) |
| SI (2) | SI1490357T1 (el) |
| SV (1) | SV2003001515A (el) |
| TW (1) | TW200306816A (el) |
| UY (1) | UY27735A1 (el) |
| WO (1) | WO2003080599A1 (el) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0207104D0 (en) * | 2002-03-26 | 2002-05-08 | Pfizer Ltd | Stable hydrate of a muscarinic receptor antagonist |
| US7244765B2 (en) * | 2004-06-25 | 2007-07-17 | Cytokine Pharmasciences, Inc | Guanylhydrazone salts, compositions, processes of making and methods of using |
| EP1874292A2 (en) * | 2005-04-24 | 2008-01-09 | Wyeth | Methods for modulating bladder function |
| US20070197630A1 (en) * | 2005-12-27 | 2007-08-23 | Valeriano Merli | Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof |
| EP2109601A2 (en) * | 2007-01-05 | 2009-10-21 | Dr. Reddy's Laboratories Ltd. | Preparation of darifenacin and its salts |
| BRPI0807615A8 (pt) * | 2007-02-23 | 2017-12-05 | Theravance Inc | Compostos de difenilmetil amônico quaternário úteis como antagonistas de receptor muscarínico |
| WO2008144602A1 (en) * | 2007-05-18 | 2008-11-27 | Auspex Pharmaceuticals, Inc. | Deuterated zamifenacin derivatives |
| US20100204296A1 (en) * | 2007-06-08 | 2010-08-12 | Actavis Group Ptc Ehf | Novel Polymorphs of Darifenacin Free Base and its Hydrobromide Salt |
| US20090005431A1 (en) * | 2007-06-30 | 2009-01-01 | Auspex Pharmaceuticals, Inc. | Substituted pyrrolidines |
| AR068322A1 (es) * | 2007-07-13 | 2009-11-11 | Medichem Sa | Forma amorfa de hidrobromuro de darifenacina y procedimientos para su preparacion |
| CZ300895B6 (cs) * | 2008-01-28 | 2009-09-02 | Zentiva, A. S. | Zpusob prípravy Darifenacinu |
| WO2009125426A2 (en) * | 2008-02-08 | 2009-10-15 | Neuland Laboratories Ltd | NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE |
| WO2009122997A1 (ja) | 2008-04-02 | 2009-10-08 | 株式会社カネカ | （ｓ）－３－（１－シアノ－１，１－ジフェニルメチル）－ピロリジンの製造法 |
| US20110144354A1 (en) * | 2008-09-22 | 2011-06-16 | Watson Pharma Private Limited | Process for Preparation of Darifenacin and Intermediates Used in the Process |
| EP2236509A1 (en) | 2009-04-01 | 2010-10-06 | Ragactives, S.L. | Method for obtaining 1,3-difunctionalized pyrrolidine derivatives |
| WO2011070419A1 (en) | 2009-12-10 | 2011-06-16 | Aurobindo Pharma Limited | An improved process for the preparation of darifenacin hydrobromide |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| EA201891416A1 (ru) * | 2015-12-14 | 2018-12-28 | Айронвуд Фармасьютикалз, Инк. | ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА |
| ES2815023T3 (es) * | 2016-08-12 | 2021-03-29 | Bayer Cropscience Ag | Procedimiento para preparar derivados de estireno sustituidos |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8906166D0 (en) * | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
| US5233053A (en) * | 1989-03-17 | 1993-08-03 | Pfizer Inc. | Pyrrolidine derivatives |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9400600D0 (en) * | 1994-01-14 | 1994-03-09 | Pfizer Ltd | Treatment of motion seckness |
| GB9518953D0 (en) * | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| GB9612710D0 (en) * | 1996-06-18 | 1996-08-21 | Pfizer Ltd | Method of treatment |
| AU4421697A (en) * | 1996-09-19 | 1998-04-14 | American Home Products Corporation | Method of treating urinary incontinence |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| GB0207104D0 (en) * | 2002-03-26 | 2002-05-08 | Pfizer Ltd | Stable hydrate of a muscarinic receptor antagonist |
-
2002
- 2002-03-26 GB GBGB0207104.1A patent/GB0207104D0/en not_active Ceased
-
2003
- 2003-03-17 BR BRPI0308706A patent/BRPI0308706B8/pt not_active IP Right Cessation
- 2003-03-17 CN CNB038070847A patent/CN100345840C/zh not_active Expired - Lifetime
- 2003-03-17 DK DK03744716.6T patent/DK1490357T3/da active
- 2003-03-17 SI SI200331973T patent/SI1490357T1/sl unknown
- 2003-03-17 JP JP2003578353A patent/JP2005524678A/ja not_active Withdrawn
- 2003-03-17 KR KR1020117027931A patent/KR101212908B1/ko active IP Right Grant
- 2003-03-17 PT PT03744716T patent/PT1490357E/pt unknown
- 2003-03-17 EP EP03744716A patent/EP1490357B1/en not_active Expired - Lifetime
- 2003-03-17 EP EP10177716A patent/EP2336124B1/en not_active Expired - Lifetime
- 2003-03-17 SI SI200332215T patent/SI2336124T1/sl unknown
- 2003-03-17 BR BR122018000397A patent/BR122018000397B8/pt not_active IP Right Cessation
- 2003-03-17 CA CA2480287A patent/CA2480287C/en not_active Expired - Lifetime
- 2003-03-17 ES ES10177716T patent/ES2394067T3/es not_active Expired - Lifetime
- 2003-03-17 DE DE60335711T patent/DE60335711D1/de not_active Expired - Lifetime
- 2003-03-17 AU AU2003209921A patent/AU2003209921A1/en not_active Abandoned
- 2003-03-17 ES ES03744716T patent/ES2358644T3/es not_active Expired - Lifetime
- 2003-03-17 AT AT03744716T patent/ATE495169T1/de active
- 2003-03-17 WO PCT/IB2003/001043 patent/WO2003080599A1/en active Application Filing
- 2003-03-17 KR KR1020047015243A patent/KR101026283B1/ko active IP Right Grant
- 2003-03-17 KR KR1020107018853A patent/KR20100101182A/ko not_active Application Discontinuation
- 2003-03-17 DK DK10177716.7T patent/DK2336124T3/da active
- 2003-03-17 KR KR1020127018787A patent/KR20120098888A/ko not_active Application Discontinuation
- 2003-03-17 PT PT101777167T patent/PT2336124E/pt unknown
- 2003-03-20 PA PA20038569701A patent/PA8569701A1/es unknown
- 2003-03-24 AR ARP030101017A patent/AR042608A1/es unknown
- 2003-03-25 UY UY27735A patent/UY27735A1/es not_active Application Discontinuation
- 2003-03-25 TW TW092106635A patent/TW200306816A/zh unknown
- 2003-03-25 SV SV2003001515A patent/SV2003001515A/es not_active Application Discontinuation
- 2003-03-25 US US10/396,887 patent/US6930188B2/en not_active Expired - Lifetime
-
2005
- 2005-07-13 US US11/180,433 patent/US20050245597A1/en not_active Abandoned
-
2006
- 2006-01-18 HK HK06100807A patent/HK1080847A1/xx not_active IP Right Cessation
-
2008
- 2008-03-17 US US12/049,660 patent/US7696357B2/en not_active Expired - Lifetime
-
2010
- 2010-06-02 JP JP2010126865A patent/JP2010195828A/ja active Pending
-
2011
- 2011-02-22 CY CY20111100213T patent/CY1111200T1/el unknown
- 2011-10-17 HK HK11111039.7A patent/HK1156626A1/xx not_active IP Right Cessation
-
2012
- 2012-11-29 CY CY20121101165T patent/CY1113433T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113433T1 (el) | Σταθερος υδριτης ενος ανταγωνιστη υποδοχεα μουσκαρινης | |
| Abbott et al. | Vocal exercise may attenuate acute vocal fold inflammation | |
| DK1835924T3 (da) | Behandling af parkinsons sygdom og beslægtede sygdomme under anvendelse af postpartum opnåede celler | |
| ATE454372T1 (de) | Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen | |
| DE60220719D1 (de) | Antikörper gegen das muc18-antigen | |
| NO20073337L (no) | Fremgangsmater for behandling av andedrettssykdommer ved anvendelse av antagonister av interleukin-1 reseptor type 1 | |
| CY1107203T1 (el) | Χρηση αναστολεων της il - 18 για τη θεραπεια και/ή την προληψη καρδιακης νοσου | |
| CY1107985T1 (el) | Ccr1 ανταγωνιστες για την αγωγη μεταξυ αλλων απομυελινωτικης φλεγμονωδους νοσου | |
| SE0002754D0 (sv) | New pharmaceutical combination formulation and method of treatment with the combination | |
| CA2710409A1 (en) | 6h-dibenz0 [b,e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists | |
| BRPI0707495A2 (pt) | método para tratar ou reduzir os sintomas de esquizofrenia, uso de um abridor seletivo de canal de potássio kcnq, método de triagem de um composto, e, uso de um composto | |
| ATE516366T1 (de) | Regulierte aptamer-therapeutika | |
| RU2007126638A (ru) | Профилактическое или терапевтическое средство для лечения расстройства сна | |
| NO20070522L (no) | Oral vedvarende frigivelsesformulering av tedisamil med gastriske bibeholdelsesegenskaper | |
| ES2331369T3 (es) | Medicina para prevencion o tratamiento de miccion frecuente o incontinencia urinaria. | |
| RU2011110517A (ru) | Новое терапевтическое применение дротаверина | |
| DOP2003000615A (es) | Hidrato estable de un antagonista de receptores muscarinicos | |
| Marszałek et al. | Estimation of influence of myofascial release techniques on esophageal pressure in patients after total laryngectomy | |
| CY1119418T1 (el) | Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη | |
| Porodko et al. | Conn's syndrome and atrial fibrillation | |
| Corboz et al. | Tachykinin NK1 receptor-mediated vasorelaxation in human pulmonary arteries | |
| JPWO2007026737A1 (ja) | 関節リウマチの予防及び／又は治療法 | |
| RU2012114668A (ru) | Способ уретропексии | |
| Tam | Validating an occupational therapist's assessment in a pre-diagnostic clinic: A strategy to improve access to arthritis care. | |
| Yugay et al. | DETERMINATION OF REHABILITATION POTENTIAL IN PATIENTS AND INVALIDS OWING TO DIABETES MELLITUS |